Research Article

The Relationship between Pre-Pandemic Interferon Gamma Release Assay Test Results and COVID-19 Infection: Potential Prognostic Value of Indeterminate IFN-γ Release Assay Results

Table 4

Comparison of groups with and without COVID-19.

ParametersCOVID-19 (+) (n = 46)COVID-19 (−) (n = 319)

Sex, n (%)
 Male27 (58.7)148 (46.4)0.118
 Female19 (41.3)171 (53.60)

Age (year), n (%)
 <309 (19.6)88 (27.6)0.284
 31–5025 (54.3)135 (42.3)
 >5012 (26.1)96 (30.1)

Body mass index (kg/m2), n (%)
 Underweight (<18.5 kg/m2)4 (8.7)45 (14.1)0.489
 Normal weight (18.5–24.9 kg/m2)21 (45.7)111 (34.8)
 Overweight (24.5–29.9 kg/m2)12 (26.1)92 (28.8)
 Obese (>30 kg/m2)9 (19.5)71 (22.3)

Smoking
 Never smoker, n (%)25 (54.4)180 (56.4)0.598
 Former smoker, n (%)10 (21.8)51 (16.0)
 Current smoker, n (%)11 (23.8)88 (27.6)

Smoking amount (pack-year), n (%)
 025 (54.4)180 (56.4)0.868
 1–107 (15.2)53 (16.6)
 11–207 (15.2)51 (16.0)
 >207 (15.2)35 (11.0)

TB history, n (%)
 Yes4 (8.7)8 (2.5)0.051
 No42 (91.3)311 (97.5)

TB subgroup, n (%)
 Lung TB2 (50.0)3 (37.5)0.894
 Extrapulmonary TB1 (25.0)3 (37.5)
 Unknown1 (25.0)2 (25.0)

Chronic disease n (%)
 HT7 (15.2)33 (10.3)0.323
 DM4 (8.7)28 (8.8)0.985
 Rheumatologic disease23 (50.0)151 (47.3)0.735
 Coronary artery disease4 (8.7)19 (6.0)0.512
 Obstructive lung diseases2 (4.3)52 (16.3)0.033
 MS4 (8.7)13 (4.1)0.249
 Malignancy3 (6.5)12 (3.8)0.417
 Hypothyroidism3 (6.5)13 (4.1)0.437
 Cardiac arrhythmia0 (0.0)7 (2.2)0.603
 IBH3 (6.5)32 (10.0)0.597
 CRF2 (4.3)9 (2.8)0.636

Drugs used, n (%)
 Biological treatments20 (43.6)149 (46.7)0.681
 Corticosteroid18 (39.1)112 (35.1)0.594

COVID-19 vaccine status, n (%)
 Done4 (8.7)46 (14.4)0.291
 Not done42 (91.3)273 (85.6)

CRF: chronic renal failure; DM: diabetes mellitus; HT: hypertension; IBD: inflammatory bowel disease; MS: multiple sclerosis; TBF: STANDARD ETB-Feron ELISA (TBF) test. value < 0.05 was considered statistically significant. Values below 0.05 are in bold and indicate statistically significant differences between two categories.